Cite this: *J. Mater. Chem. B*, 2015, **3**, 9182

Receptor-targeting fluorescence imaging and theranostics using a graphene oxide based supramolecular glycoconjugate†

Ding-Kun Ji,^{‡a} Yue Zhang,^{‡ab} Yi Zang,^{*b} Wang Liu,^c Xiongwen Zhang,^c Jia Li,^{*b} Guo-Rong Chen,^a Tony D. James^d and Xiao-Peng He^{*a}

Intercellular glycoligand-receptor interactions are implicated in a number of disease-related processes. Effective tools that target these receptors may facilitate disease theranostics. However, owing to their low binding affinity, multivalent presentation of glycoligands is needed to increase the avidity with transmembrane receptors. While previous strategies focus on the covalent coupling of glycoligands to a synthetic backbone, we show here that the use of graphene oxide (GO) greatly enhances the cellular and tissue imaging ability of a small-molecule fluorescence glycoprobe. We determine that GO with an optimum size may serve as a clustering platform to reinforce the interaction of the glycoprobe with its selective receptor on a cancer cell. This phenomenon has been consistently observed with the xenograft tissue of a tumor-bearing mouse. Using this principle we have further constructed a supramolecular glycoconjugate by co-assembling the glycoprobe and an anticancer drug onto a single GO surface. In addition to imaging ability, this material displays improved toxicity for liver cancer cells that over express the glycoprotein receptor, when compared to the control cells.

Received 3rd October 2015,
Accepted 6th November 2015

DOI: 10.1039/c5tb02057c

www.rsc.org/MaterialsB

Introduction

Intercellular ligand-receptor interactions are crucial for the initiation of numerous physiological and pathological events. For example, the galectins, which recognize galactose-terminated glycoconjugates, are over-secreted during the progression of cancer, inflammation and heart disease. In the process of influenza virus invasion, sialic acid-terminated oligosaccharides of human cells are recognized by the hemagglutinins expressed on the viral particle surface, facilitating virus invasion. Another class of transmembrane receptors are the C-type lectins, which are distributed on specific types of cells.^{1–3} They can interact with selective glycoligands (glycans) to promote human diseases.^{4,5}

As a consequence, effective methods to probe these dynamic events directly on the cellular level are important for the advancement of chemical glycobiology and disease theranostics.

Considering the low affinity between a glycoligand and the receptor, the ligands require multivalent presentation to increase the binding avidity. Many elegant methods have been developed to construct multivalent glycopolymers^{6,7} and glycoconjugates⁸ to address the avidity. However, these methods mainly focus on the covalent coupling of glycoligands to a synthetic backbone, which might increase the complexity of probe preparation. Recently, we^{9–13} and others^{14–21} have shown that fluorogenic composite materials (FCMs) that feature a material substrate (especially graphene oxide [GO]) on which a fluorophore-tagged ligand is self-assembled are emerging as promising biosensing materials owing to their ease of preparation and manipulation, low cost and ability to capture receptor expression of live cells.

Here, we uncover that the addition of GO greatly enhances the receptor-targeting cellular imaging effect of a small-molecule fluorescence glycoprobe. We determined that GO with an optimum size may act as a clustering platform to reinforce the selective interaction between the glycoprobe and receptor on a cancer cell. This phenomenon has been consistently observed with the xenograft tissue of a tumor-bearing mouse. Using this principle we have further constructed a supramolecular glycoconjugate by co-assembling the glycoprobe and an anticancer drug onto a

^a Key Laboratory for Advanced Materials & Institute of Fine Chemicals, East China University of Science and Technology, 130 Meilong Rd., Shanghai 200237, P. R. China. E-mail: xphe@ecust.edu.cn; Fax: +86-21-64252758; Tel: +86-21-64253016

^b National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P. R. China. E-mail: yzang@simm.ac.cn, jli@simm.ac.cn

^c Institute of Drug Discovery and Development, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, East China Normal University (ECNU), 3663 N. Zhongshan Rd., Shanghai 200062, P. R. China

^d Department of Chemistry, University of Bath, Bath, BA2 7AY, UK

† Electronic supplementary information (ESI) available: Additional figures, experimental section and additional references. See DOI: 10.1039/c5tb02057c

‡ Equal contribution.

Fig. 1 (a) Conditions and reagents: (i) $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$, sodium ascorbate in $\text{CH}_2\text{Cl}_2/\text{H}_2\text{O}$ (10/1, v/v), and then Et_3N . (b) Schematic illustration of the formation of the GO-based supramolecular glycoconjugate for receptor-targeting theranostics. GO = graphene oxide; CPT = camptothecin.

single GO surface. In addition to imaging ability, this material displays improved toxicity for liver cancer cells that over express the glycoprotein receptor, when compared to the control cells without receptor expression (Fig. 1).

Results and discussion

The glycoprobe (**DK1**, Fig. 1a) was synthesized by a click reaction between alkyne galactoside **1** and an azido dicyanomethylene **2** (Fig. 1a), according to a previous protocol.²² The galactosyl moiety can be recognized by the transmembrane asialoglycoprotein receptor (ASGPr) selectively expressed on hepatocytes (we used Hep-G2, a human hepatoma cell line), while the fluorophore can produce an optical signal and self-assemble to the surface of GO *via* π -stacking and other forces of interaction such as van der Waals and hydrogen-bonding.^{9–14} The fluorescence imaging of **DK1** for ASGPr-rich Hep-G2²³ was carried out and optimized in the absence and presence of a series of GOs with different sizes (**G0**: 0–10 nm; **G1**: 50–200 nm; **G2**: 200–500 nm; **G3**: 500–1000 nm). The atomic force microscopic characterization of the GOs is shown in Fig. S1 (ESI†).

We observed that, among the GOs used, the presence of **G1** and **G2** produced an increased cellular fluorescence compared to **DK1** alone (Fig. 2a and c). In contrast, the presence of **G0** and **G3** did not cause the same level of fluorescence enhancement. To confirm that the observed fluorescence imaging results were based on selective galactose-ASGPr interactions, we used a modified Hep-G2 cell line with a reduced expression level of ASGPr (sh-ASGPr)^{10,24} as well as other cancer cell lines derived from different tissues (human cervix cancer Hela,

Fig. 2 Fluorescence imaging (a) and quantification (c) of Hep-G2 cells with **DK1** (40 μM) in the absence or presence of **G0**, **G1**, **G2** and **G3** (50 $\mu\text{g mL}^{-1}$). Fluorescence imaging (b) and quantification (d) of different human cancer cell lines using **DK1@G2** (40 $\mu\text{M}/50 \mu\text{g mL}^{-1}$) (Hep-G2: human liver cancer; sh-ASGPr: Hep-G2 cells with reduced expression level of the asialoglycoprotein receptor (ASGPr); Hela: human cervix cancer; A549: human lung cancer; HCT-116: human colon cancer; MCF-7: human breast cancer). (e) Relative mRNA level of ASGPr of different cells determined by real-time quantitative polymerase chain reaction (*** $P < 0.001$; n. d. means not detectable). Excitation channel: 520–550 nm; emission: 580–650 nm. Scale bar: 100 μm .

human lung cancer A549, human colon cancer HCT-116 and human breast cancer MCF-7) as negative controls. With the optimal imaging condition (40 $\mu\text{M}/50 \mu\text{g mL}^{-1}$), we observed that **DK1@G2** produced minimal fluorescence upon incubation with sh-ASGPr and other cancer cells (Fig. 2b and d). Moreover, pre-incubation of increasing free D-galactose gradually lowered the fluorescence generated in Hep-G2 cells (Fig. S2, ESI†). We also determined that the fluorescence intensity produced by **DK1@G2** (Fig. 2d) was in good agreement with the ASGPr expression level of the different cells (Fig. 2e), and that the presence of increasing **DK1** and **DK1@G2** barely suppressed the viability of Hep-G2 cells determined by two independent cell viability counting assays (Fig. S3, ESI†). All these observations suggest that the fluorescence imaging results observed at the cellular level are predominantly based on galactose-ASGPr recognition. To test the cellular localization of the glycoprobe, confocal microscopy was used. The imaging result suggested that **DK1** was endocytosed and trafficked to the lysosome, which is confirmed by co-localization with a lysotracker (Fig. S4, ESI†).

With these results in hand, we then used a mouse model with a liver tumor to test the GO effect at the tissue level. Female athymic BALB/c nu/nu mice with Hep-G2 tumor xenograft were

Fig. 3 Fluorescence imaging (a) and quantification (c) of Hep-G2 xenograft slice of female athymic BALB/c nu/nu mice with **DK1** (40 μM) in the absence and presence of **G0**, **G1**, **G2** and **G3** (50 μg mL⁻¹). Fluorescence imaging (b) and quantification (d) of different tissue slices including liver, heart, spleen and lung with **DK1@G2** (40 μM/50 μg mL⁻¹). Excitation channel: 520–550 nm; emission: 580–650 nm. Scale bar: 200 μm.

established according to a previous report,²⁵ and the tumor, liver, lung, heart and spleen were removed to prepare tissue sections. By incubation of **DK1** with the tumor sections in the absence or presence of GO, we determined that **DK1@G2** (40 μM/50 μg mL⁻¹, the optimal concentration used for cellular imaging) resulted in a stronger fluorescence imaging of the tumor than **DK1** alone and other **DK1@GOs** (Fig. 3a and c). We also observed that **DK1@G2** selectively stained the Hep-G2 tumor xenograft and liver among other sections from the animal model (Fig. 3b and d). This observation accords with the fact that the galactose-selective ASGPr is only over-expressed on the tumor and liver, but not on heart, spleen and lung (Fig. S5, ESI†).²⁶ These results suggest that, similar to the observation on the cellular level, the selective galactose ligand–ASGP receptor based fluorescence imaging is enhanced by GO probably due to the multivalent display of **DK1**.

From our previous work, we have demonstrated that amongst GOs of different sizes, **G2** enhances the interaction between **DK1** and a selective lectin receptor to the greatest extent.²² Spectroscopic measurements suggest that both the size and oxygen content of the GO have an impact on the ligand–receptor interactions. On the one hand, increasing the size, reduces the oxygen content of a GO, leading to a stronger adsorption of dye molecules but weaker adsorption of proteins. Therefore, GO with larger sizes (such as **G3** with 500–1000 nm size range) might bind more strongly with dye molecules, whilst compromising

the binding with a lectin receptor. However, a decrease of size increases the oxygen content and this might enhance the association between the GO (such as **G0**) and a protein, whilst decreasing the amount of glycoprobe–GO assembly, thus lowering the ability of the GO to augment the protein–ligand binding. Therefore, we deduced that the medium-sized GOs (such as **G1** and **G2**) have an optimal size as well as oxygen content to promote the multivalent glycoligand–receptor interactions.²² Similarly, these observations may be applicable for glycoprobe–transmembrane receptor interactions. However, due to the complexity of the cellular environment, more sophisticated experiments and structurally more defined GOs are required to fully elaborate the observed GO size effect.

With this GO-based multivalent strategy, we sought to further construct a supramolecular glycocomposite by the co-assembly of **DK1** and an anticancer drug (camptothecin – **CPT**) to a single GO surface for receptor-targeting theranostics. **G2** with the best imaging effect was used to assemble with **DK1** and **CPT** at two different concentrations. We observed that the glycocomposites retained their fluorescence imaging ability with selectively for Hep-G2 cells over the other control cells tested (Fig. 4a and b). Then, we measured the toxicity of the glycocomposites for the cancer cells (Fig. 4). While **CPT** alone showed insignificant (1 μM – low concentration group) or moderate (10 μM – high concentration group) toxicity upon a short-time incubation (15 min) with the cancer cells, the presence of **G2** enhanced the toxicity of the low-concentration group. This is in agreement with the reported drug delivering ability of graphene to improve cancer therapy.²⁷ Interestingly, in both groups, the presence of **DK1** selectively enhanced the toxicity for Hep-G2 that highly express

Fig. 4 Fluorescence imaging (a) and quantification (b) of different cells with the supramolecular **DK1@G2@CPT** (**DK1**: 40 μM; **G2**: 50 μg mL⁻¹). (c) Viability of different cells upon treatment with **CPT**, **CPT@G2** and **DK1@G2@CPT**. Excitation channel: 520–550 nm; emission: 580–650 nm. Scale bar: 100 μm.

ASGPr, but not for HeLa and A549 without receptor expression, in a concentration-dependent manner. These data suggest the suitability of using the supramolecular glycomposites for receptor-targeting cancer theranostics. Our supramolecular strategy could also be extended to other biomolecular systems for specific cellular targeting.²⁸

Conclusions

We have determined that GO can enhance the cellular and tissue imaging effect of a small-molecule fluorescence glycoprobe. This phenomenon could probably be reasoned by the clustering effect of GO for the fluorophore-labelled glycoligands, increasing the avidity with transmembrane receptors. Moreover, this non-covalent, multivalent strategy has proven suitable for the construction of a unique supramolecular glycomposite comprising both the glycoprobe and an anticancer drug. With retained fluorescence imaging ability, this glycomposite material displayed enhanced toxicity for liver cancer cells with ASGPr expression, but not for the control cells without the receptor expression. This research suggests a unique GO-based supramolecular strategy for receptor-targeting disease theranostics.

Acknowledgements

We thank the 973 project (2013CB733700), the Fundamental Research Funds for Central Universities (222201414010), the Key Project of Shanghai Science and Technology Commission (13NM1400900) and the National Science Foundation of China (21572058, 21576088 and 91213303). The Catalysis And Sensing for our Environment (CASE) network is thanked for research exchange opportunities. Prof. He Tian is thanked for his helpful discussion. Prof. Juan Xie (ENS de Cachan) is thanked for kindly providing synthetic intermediates.

Notes and references

- 1 C. R. Bertozzi and L. L. Kiessling, *Science*, 2001, **291**, 2357–2364.
- 2 T. Feizi and W. Chai, *Nat. Rev. Mol. Cell Biol.*, 2004, **5**, 582–588.
- 3 G. W. Hart and R. J. Copeland, *Cell*, 2010, **143**, 672–676.
- 4 F.-T. Liu and G. A. Rabinovich, *Nat. Rev. Cancer*, 2005, **5**, 29–41.
- 5 J. Mukherjee, H. J. de Haas, A. D. Petrov, A. Tawakol, N. Haider, A. Tahara, C. C. Constantinescu, J. Zhou, H. H. Boersma, T. Imaizumi, M. Nakano, A. Finn, Z. Fayad, R. Virmani, V. Fuster, L. Bosca and J. Narula, *Nat. Med.*, 2014, **20**, 215–219.
- 6 L. L. Kiessling and R. A. Splain, *Annu. Rev. Biochem.*, 2010, **79**, 619–653.
- 7 L. L. Kiessling and J. C. Grim, *Chem. Soc. Rev.*, 2013, **42**, 4476–4491.
- 8 (a) S. Cecioni, A. Imberty and S. Vidal, *Chem. Rev.*, 2015, **115**, 525–561; (b) Z. Yu, R. Paul, C. Bhattacharya, T. C. Bozeman, M. J. Rishel and S. M. Hecht, *Biochemistry*, 2015, **54**, 3100–3109; (c) Z. Yu, R. M. Schmaltz, T. C. Bozeman, R. Paul, M. J. Rishel, K. S. Tsosie and S. M. Hecht, *J. Am. Chem. Soc.*, 2013, **135**, 2883–2886.
- 9 X.-P. He, Y. Zang, T. D. James, J. Li and G.-R. Chen, *Chem. Soc. Rev.*, 2015, **44**, 4239.
- 10 H.-L. Zhang, X.-L. Wei, Y. Zang, J.-Y. Cao, S. Liu, X.-P. He, Q. Chen, Y.-T. Long, J. Li, G.-R. Chen and K. Chen, *Adv. Mater.*, 2013, **25**, 4097–4101.
- 11 D.-K. Ji, G.-R. Chen, X.-P. He and H. Tian, *Adv. Funct. Mater.*, 2015, **25**, 3483.
- 12 X.-P. He, Q. Deng, L. Cai, C.-Z. Wang, Y. Zang, J. Li, G.-R. Chen and H. Tian, *ACS Appl. Mater. Interfaces*, 2014, **6**, 5379–5382.
- 13 X. Sun, B. Zhu, D.-K. Ji, Q. Chen, X.-P. He, G.-R. Chen and T. D. James, *ACS Appl. Mater. Interfaces*, 2014, **6**, 10078–10082.
- 14 L. Wang, K.-Y. Pu, J. Li, X. Qi, H. Li, H. Zhang, C. Fan and B. Liu, *Adv. Mater.*, 2011, **23**, 4386–4391.
- 15 F. Li, H. Pei, L. Wang, J. Lu, J. Gao, B. Jiang, X. Zhao and C. Fan, *Adv. Funct. Mater.*, 2013, **23**, 4140–4148.
- 16 K. P. Loh, Q. Bao, G. Eda and M. Chhowalla, *Nat. Chem.*, 2010, **2**, 1015–1024.
- 17 E. Morales-Narváez and A. Merkoçi, *Adv. Mater.*, 2012, **24**, 3298–3308.
- 18 L. Feng, L. Wu and X. Qu, *Adv. Mater.*, 2013, **25**, 168–186.
- 19 C.-H. Lu, H.-H. Yang, C.-L. Zhu, X. Chen and G.-N. Chen, *Angew. Chem., Int. Ed.*, 2009, **48**, 4785–4787.
- 20 C. Chung, Y.-K. Kim, D. Shin, S.-R. Ryoo, B. H. Hong and D.-H. Min, *Acc. Chem. Res.*, 2013, **46**, 2211–2224.
- 21 H. Jang, J. Lee and D.-H. Min, *J. Mater. Chem. B*, 2014, **2**, 2452–2460.
- 22 D.-K. Ji, Y. Zhang, X.-P. He and G.-R. Chen, *J. Mater. Chem. B*, 2015, **3**, 6656–6661.
- 23 E. I. Rigopoulou, D. Roggenbuck, D. S. Smyk, C. Liaskos, M. G. Mytilinaiou, E. Feist, K. Conrad and D. P. Bogdanos, *Autoimmun. Rev.*, 2012, **12**, 260–269.
- 24 Z. Li, S.-S. Deng, Y. Zang, Z. Gu, X.-P. He, G.-R. Chen, K. Chen, T. D. James, J. Li and Y.-T. Long, *Sci. Rep.*, 2013, **3**, 2293.
- 25 S. Mukhopadhyay, P. K. Panda, D. S. Das, N. Sinha, B. Behera, T. K. Maiti and S. K. Bhutia, *Acta Pharmacol. Sin.*, 2014, **35**, 814–824.
- 26 F. Lv, X. He, L. Wu and T. Liu, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 1878–1882.
- 27 X. Sun, Z. Liu, K. Welsher, J. T. Robinson, A. Goodwin, S. Zaric and H. Dai, *Nano Res.*, 2008, **1**, 203–212.
- 28 Y. Wen, W. Liu, C. Bagia, S. Zhang, M. Bai, J. M. Janjic, N. Giannoukakis, E. S. Gawalt and W. S. Meng, *Acta Biomater.*, 2014, **10**, 4759–4767.